Premium
P2–412: MPC–7869 (R–flurbiprofen), a selective Aβ42–lowering agent, delays time to clinically significant psychiatric events in Alzheimer's disease (AD): Analysis from a 12–month phase 2 trial
Author(s) -
Mintzer Jacobo E.,
Wilcock Gordon K.,
Black Sandra E.,
Zavitz Kenton H.,
Hendrix Suzanne B.
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.1253
Subject(s) - placebo , adverse effect , medicine , dosing , exploratory analysis , donepezil , disease , psychiatry , dementia , pathology , alternative medicine , computer science , data science
A 42-LOWERING AGENT, DELAYS TIME TO CLINICALLY SIGNIFICANT PSYCHIATRIC EVENTS IN ALZHEIMER’S DISEASE (AD): ANALYSIS FROM A 12-MONTH PHASE 2 TRIAL Jacobo E. Mintzer, Gordon K. Wilcock, Sandra E. Black, Kenton H. Zavitz, Suzanne B. Hendrix, MPC-7869 Phase 2 Study Investigators, Department of Psychiatry, Medical University of South Carolina, Charleston, SC, USA; University of Bristol, Bristol, United Kingdom; Sunnybrook & Women’s, University of Toronto, Toronto, ON, Canada; Myriad Pharmaceuticals, Salt Lake City, UT, USA. Contact e-mail: kzavitz@myriad.com